L. Michael Glodé, MD, FACP
Professor, Robert Rifkin Chair for Prostate Cancer Research
Page Content
 |
Education: MD
Washington University SOM, St. Louis, MO – 1972
Residency: Internal Medicine, UT Southwestern, 1972-1974
Fellowship: Immunology, NIH, 1975-1976
Fellowship: Medical Oncology, Dana Farber/Harvard 1976-1978
Fogarty International Fellowship: Molecular Biology, Helsinki 1985-1986
|
|
Associate Director for Community Engagement, University of Colorado Cancer Center
Medical Director, Genitourinary Oncology Program, University of Colorado Hospital
Dr. Glodé was the first board-certified Medical Oncologist at the University of Colorado, joining the faculty after training at Dana-Farber Cancer Institute.
Research
Dr. Glodé's research has been clinically focused on prostate cancer for many years. He headed the initial research on leuprolide, leading to it’s approval and subsequently developed a “single shot” castration agent that is in animal trials. He has also led efforts to evaluate a natural product, silibinin as a preventive or therapeutic agent and has been an investigator on more than 30 clinical trials, including the PI position for the largest adjuvant trial in prostate cancer, SWOG 9921. He has received numerous teaching awards and founded the AACR course “Molecular Biology for Clinical Oncologists” as well as serving as Founding Editor of the ASCO website, www.asco.org.
Publications
PubMed Articles
Funding
NIH
Pfizer
Bristol-Myers Squibb
Cell Genesis
Dendreon
|